- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Observational
- Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 50
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer, Early-stage Breast Cancer
- Interventions
- Prescreening, Screening and Enrollment, Baseline, Interpret BMI, Interpret HbA1c, Interpret lipid panel and assess other risk factors, Assess 10 year risk of cardiovascular event, Recommendations, Follow-Up
- Other · Behavioral
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Sarcoma
- Interventions
- Non-Metastatic and Resectable, Metastatic and Un-resectable, No evidence of disease, under surveillance, ALT or WDLS
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Charlotte, North Carolina • Winston-Salem, North Carolina
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
- Interventions
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
- Drug · Procedure · Other
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
- Conditions
- Tobacco Dependence
- Interventions
- CEASE, CEASE + BIO
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 865 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- HPV-Related Squamous Cell Carcinoma, HNSCC
- Interventions
- nab-paclitaxel, Carboplatin, Nivolumab, Cisplatin, Hydroxyurea, 5-FU, Dexamethasone, Famotidine, Diphenhydramine, Paclitaxel, Transoral robotic surgery (TORS), Adjuvant RT, Chemoradiotherapy
- Drug · Procedure · Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pancreatic Cancer
- Interventions
- medical chart review, questionnaire administration, study of socioeconomic and demographic variables, biopsy
- Other · Procedure
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 100 Years
- Enrollment
- 379 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Graft Versus Host Disease
- Interventions
- RGI-2001, Calcineurin Inhibitors, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning Regimen, Allogeneic Bone Marrow Transplantation, Methotrexate, Mofetil Mycophenolate, sirolimus
- Drug · Procedure
- Lead sponsor
- Regimmune Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 6
- States / cities
- San Diego, California • Stanford, California • Tampa, Florida + 3 more
- Conditions
- High Risk Solid Tumors, Recurrent Solid Tumors
- Interventions
- Peripheral Blood Stem Cell Transplant
- Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 35 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Myeloma
- Interventions
- Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
- Drug · Other
- Lead sponsor
- Robert Redner, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 22
- States / cities
- Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
- Conditions
- Breast Cancer
- Interventions
- sargramostim, therapeutic autologous dendritic cells, trastuzumab, vinorelbine ditartrate
- Biological · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2017
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Follicular Lymphoma
- Interventions
- Personalized tumor vaccine, Poly ICLC, Nivolumab, Peripheral blood draws, Leukapheresis, Rituximab, Biopsy
- Biological · Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Breast Cancer
- Interventions
- Hypofractionated radiotherapy, Pembrolizumab infusion, Blood and tissue sampling
- Radiation · Drug · Procedure
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
- Interventions
- Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Malignant Testicular Germ Cell Tumor
- Interventions
- Clinical Stage I Disease, Clinical Stage I with relapse, CSII Disease
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 2 more
- Conditions
- Cancer
- Interventions
- anti-thymocyte globulin, rituximab, clofarabine, stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Breast Cancer
- Interventions
- Hydroxychloroquine (HCQ), Gedatolisib
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- CD33KO-HSPC; CART33
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2044
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- Aerobic Training, Educational Information, Supervised Home Based Training
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years to 80 Years · Female only
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Cancer of Breast, Cancer of the Breast
- Interventions
- Breast-conserving surgery (BCS), Cavity shave margins (CSM), BREAST-Q Questionnaire, 3-D breast imaging, Indocyanine green, Intraoperative imaging device, Peripheral blood draw
- Procedure · Behavioral · Device + 1 more
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 85 Years · Female only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
- Interventions
- anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Triple-Negative Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Carcinoma, Squamous Cell, Advanced Solid Tumors
- Interventions
- TAK-659, Nivolumab
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 9
- States / cities
- La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 6 more
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Lymphoid Leukemia
- Interventions
- Dasatinib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- HER-2 Gene Amplification
- Interventions
- Cisplatin, Capecitabine, Trastuzumab and MM-111, Lapatinib +/- Trastuzumab and MM-111, Paclitaxel, Trastuzumab and MM-111, Lapatinib, trastuzumab, paclitaxel, and MM-111, Docetaxel, trastuzumab and MM-111
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 15
- States / cities
- Denver, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 12 more